Xiaomei Shu Email & Phone Number | Experienced on phase 3 oncology and bone area study. paticipated important study: 1.Bone: AMGEN EVENITY(romosozumab) for the treatment of osteoporosis. had been approval by FDA and PMDA 2.Oncology: AMGEN CANDOR study combine KYPROLIS and DARZALEX. which meets primary endpoint of progression-free survival

Xiaomei Shu

Experienced on phase 3 oncology and bone area study. paticipated important study: 1.Bone: AMGEN EVE...
Chengdu, Chengdu, China

*50 free lookup(s) per month.

Xiaomei Shu’s Phone Numbers +1 781-434-****

Get XIAOMEI’s Phone Number (For Free)

Social Media

Xiaomei Shu’s Location Chengdu, Chengdu, China

Xiaomei Shu’s Current Industry Parexel

Xiaomei Shu’s Prior Industry American Institutes For Research | Qihu360 | Beijing Zhifengtang Biology | Beijing Xinjingke Biotechnology

Find accurate emails & phone numbers for over 700M professionals.

Senior Biostatistician

Present

Senior Biostatistician

2021-05-01 00:00:00 - Present

Research Assistant

2016-02-01 00:00:00 - 2016-11-01 00:00:00

Data Analyst

2012-07-01 00:00:00 - 2013-07-01 00:00:00

Specialist Marketing

2011-04-01 00:00:00 - 2012-05-01 00:00:00

Sales Agent (Promoted From Intern)

2010-04-01 00:00:00 - 2011-04-01 00:00:00

No Skills Available

No Languages Available

Xiaomei Shu is a Experienced on phase 3 oncology and bone area study. paticipated important study: 1.Bone: AMGEN EVENITY(romosozumab) for the treatment of osteoporosis. had been approval by FDA and PMDA 2.Oncology: AMGEN CANDOR study combine KYPROLIS and DARZALEX. which meets primary endpoint of progression-free survival

Xiaomei Shu has prior
experience in the following industries:
American Institutes For Research | Qihu360 | Beijing Zhifengtang Biology | Beijing Xinjingke Biotechnology

Xiaomei Shu has the following professional experience:
Parexel International | Parexel | American Institutes For Research | Qihu360 | Beijing Zhifengtang Biology | Beijing Xinjingke Biotechnology